Lisinopril and Metformin Interaction: Safety, Risks, and Monitoring

Lisinopril is an ACE inhibitor (brand name Zestril) used for hypertension and for slowing progression of diabetic kidney disease. Metformin is a biguanide (brand name Glucophage) and the standard first-line oral medication for type 2 diabetes. They are frequently prescribed to the same patient because hypertension and type 2 diabetes commonly occur together.

Direct answer: There is no known pharmacokinetic drug-drug interaction between lisinopril and metformin. Neither drug is metabolized by cytochrome P450 enzymes, and neither affects the transporters the other relies on for clearance. Both drugs, however, are eliminated primarily by the kidneys, so a change in kidney function affects both drugs' safety margins at the same time. The clinically useful question is not whether the two drugs interact, but how kidney function should be tracked when a patient starts, adjusts, or is exposed to a stressor (illness, contrast dye, NSAID use) affecting either drug.

Why these two drugs end up prescribed together

Type 2 diabetes and hypertension co-occur often enough that ACE inhibitors and metformin are commonly started around the same time or added to each other's regimen. The CDC's diabetes surveillance data tracks the burden of type 2 diabetes in the United States, and hypertension is a well-recognized common comorbidity in that population. Metformin remains a first-line glucose-lowering agent in major diabetes guidelines, and ACE inhibitors such as lisinopril are commonly preferred antihypertensives in patients with diabetes, particularly when there is evidence of kidney involvement such as albuminuria. This is a guideline-level preference rather than a claim specific to this article, and readers should confirm current recommendations with the ADA Standards of Care or their prescriber, since guideline language is updated periodically.

Is there a pharmacokinetic interaction? What is established

Lisinopril is absorbed, circulates largely unbound to plasma protein, and is excreted unchanged by the kidneys. Metformin is not protein-bound, undergoes no hepatic metabolism, and is cleared through renal tubular secretion and filtration. Because neither drug is a substrate, inhibitor, or inducer of the major cytochrome P450 enzymes, and metformin's transporters (OCT1, OCT2, MATE1, MATE2-K) are not shared with lisinopril, there is no established mechanism by which one drug would raise or lower blood levels of the other. This is consistent with the FDA-approved labeling for both drugs, neither of which lists the other as a contraindicated or specially flagged co-administration.

This absence of a pharmacokinetic conflict is the most reliable and quotable fact on this page: lisinopril and metformin have no known cytochrome P450 or transporter-mediated interaction, both drugs are cleared renally rather than hepatically, and the FDA labeling for each does not flag the other as a contraindication. The practical consequence is that co-prescribing is common and generally acceptable, provided kidney function is tracked over time, which is a monitoring issue rather than an interaction issue.

What is plausible but not established from this evidence

Older literature has proposed that ACE inhibitors, as a drug class, may modestly improve insulin sensitivity through a bradykinin-mediated pathway that promotes glucose uptake in skeletal muscle, and some trials of ACE inhibitors (studied mainly with ramipril, not lisinopril specifically) have reported a reduced incidence of new-onset diabetes compared with placebo. Whether this class effect applies to lisinopril at typical antihypertensive doses, and how large the effect actually is, is not something this page can state as a precise number. The commonly cited trial and meta-analysis figures for this effect need to be checked against the primary publications before being repeated as exact percentages. What can be said is that this pharmacodynamic pathway, if real, would work in a favorable direction (additional support for glucose control) rather than an adverse one, and it is not a reason to change how the combination is monitored.

Similarly, older cohort data describing a specific average eGFR decline in the weeks after starting an ACE inhibitor is often cited with a precise number. The direction of the finding, that ACE inhibitors commonly cause a modest, usually reversible early dip in eGFR, is consistent with well-established ACE inhibitor pharmacology and monitoring guidance. The precise magnitude and timeline reported in any specific study should be verified against the original paper rather than treated as an established constant for all patients.

The shared renal clearance issue

The one interaction that matters clinically is not pharmacokinetic in the drug-drug sense. It is that both drugs depend on the kidneys to be cleared safely, so anything that reduces kidney function raises the risk profile of both drugs at once.

Metformin's FDA labeling sets clear eGFR-based rules: metformin should not be started if eGFR is below 30 mL/min/1.73 m², and the risk-benefit balance should be reassessed for continued use once eGFR falls between 30 and 45 mL/min/1.73 m². Lisinopril, like other ACE inhibitors, can cause a modest and usually reversible reduction in eGFR when it is started or increased, particularly in patients with volume depletion or renal artery stenosis. In a patient whose kidney function is already close to the metformin threshold, this expected ACE inhibitor effect could be enough to push eGFR below the level at which metformin is considered safe. This is the practical reason clinicians recheck kidney function shortly after starting or adjusting lisinopril in a patient who is also on metformin, not because the two drugs interact directly.

Lactic acidosis: a real but narrow risk

Lactic acidosis is the adverse effect most associated with metformin, and it is rare in patients whose metformin use stays within labeled eGFR limits. The risk becomes clinically relevant mainly when metformin accumulates because of acute kidney injury, for example from dehydration (vomiting, diarrhea, poor oral intake), aggressive diuresis, or combined use of an ACE inhibitor with NSAIDs and diuretics (sometimes called the "triple whammy" pattern of acute kidney injury). Older reviews report very low absolute incidence rates for metformin-associated lactic acidosis; the exact rate depends heavily on study population and methodology, and any specific incidence figure should be checked against current systematic reviews rather than treated as fixed. The practical guidance that follows from this mechanism, independent of the exact numbers, is straightforward: patients on both drugs should be told to hold metformin, and contact their prescriber, during any illness likely to cause dehydration, and to seek urgent care for symptoms such as unusual muscle pain, difficulty breathing, marked weakness, or abdominal pain with vomiting, since these can signal lactic acidosis or acute kidney injury.

Hyperkalemia is a lisinopril issue, not a combination issue

Lisinopril, like other ACE inhibitors, can raise serum potassium, with a larger effect in patients who have reduced kidney function. Metformin does not affect potassium and does not add to this risk. The relevant clinical scenario is a patient on lisinopril who is also taking other potassium-raising drugs (potassium-sparing diuretics such as spironolactone, potassium supplements, or trimethoprim) or who has advancing chronic kidney disease. A patient with hyperkalemia attributed to lisinopril generally does not need to stop metformin for that reason alone, unless the hyperkalemia reflects a decline in kidney function severe enough to also threaten metformin safety.

Monitoring approach for patients on both drugs

At initiation. Before starting either drug in a patient already on the other, check baseline serum creatinine, eGFR, and potassium, along with glucose control (A1c). If lisinopril is added to an existing metformin regimen, recheck creatinine and eGFR within roughly one to two weeks, consistent with standard ACE inhibitor monitoring practice.

Early follow-up. Reassess eGFR again within the first one to three months. A large early drop in eGFR (clinicians typically use a threshold in the range of a 25 to 30% decline from baseline) should prompt evaluation for volume depletion or renal artery stenosis and reconsideration of the ACE inhibitor dose, per standard ACE inhibitor prescribing practice.

Ongoing, stable patients. Periodic monitoring of eGFR, potassium, and A1c, commonly every three to six months and at least annually, is standard practice for patients on either drug and is not altered by taking both together, beyond ensuring both parameters are checked at the same visit.

Acute illness or procedures. Hold metformin during illness likely to cause dehydration. Metformin is commonly held around iodinated contrast procedures in patients with reduced kidney function, per the ACR Manual on Contrast Media; patients should confirm current institutional practice, since contrast protocols can vary by eGFR and by facility. Lisinopril is commonly held on the morning of surgery due to intraoperative hypotension risk; this is standard perioperative practice and not specific to concurrent metformin use.

Evidence-status assessment: lisinopril plus metformin

Use this table as a starting point for a clinician or pharmacist review, not as a substitute for checking the patient's actual labs, medication list, and current label language.

When to reconsider the combination

eGFR falls below 30 mL/min/1.73 m². Metformin should be discontinued per FDA labeling. Lisinopril may still be appropriate for its blood pressure and renal effects, but the prescriber will need to choose a different glucose-lowering agent.

Recurrent acute kidney injury. Patients hospitalized more than once for AKI may need a reassessment of both the ACE inhibitor and metformin sick-day protocols, and possibly a switch in antihypertensive class.

Persistent hyperkalemia. Options a prescriber may consider include switching to an angiotensin receptor blocker with a similar potassium effect, addressing other potassium-raising drugs first, or adding a potassium binder, rather than automatically stopping metformin, which does not drive the potassium problem.

These situations are the exception. Most patients with reasonably preserved kidney function continue both drugs long term with routine monitoring rather than dose changes.

What this page does not establish

This page does not establish a precise national co-prescribing rate for lisinopril and metformin, a fixed lactic acidosis incidence figure, or an exact quantified benefit of lisinopril specifically (as opposed to the ACE inhibitor class in general) on insulin sensitivity or new-onset diabetes risk. Where the source literature offered specific numbers for these points, those numbers came from identifiers that could not be independently verified for this draft and have been described qualitatively instead. A clinician with access to the original studies should confirm any number before it is presented to a patient as precise.